Omar Castaneda Puglianini, MD, discusses earlier CAR T-cell therapy use, sequencing with bispecific antibodies, and access barriers in multiple myeloma.
|Videos|July 27, 2011
Donna Berry Describes the ESRA-C Program
Author(s)Donna L. Berry, PhD, RN
Donna Berry Describes the Electronic Self-Report Assessment for Cancer (ESRA-C) Program
Advertisement
Donna Berry, PhD, RN, AOCN®, FAAN, from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute describes her research in the Electronic Self-Report Assessment for Cancer (ESRA-C) program which provides a series of questions about symptoms, side effects, and quality-of-life concerns.
Advertisement
Related to this article
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
The FDA granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.
Roswell Park Comprehensive Cancer Center has earned national recognition in 2026 from the American Medical Association as a Joy in Medicine organization.
A planned interim analysis of the radiopharmaceutical RYZ101 showed improved PFS by blinded independent central review vs standard of care.
Conditional approvals in Armenia cover botensilimab plus balstilimab indicated for patients with MSS mCRC without active liver metastases.
The top 5 OncLive TV videos of the week.
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
Advertisement
Advertisement
Trending on OncLive
1
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
2
Poll Results Highlight Breast Cancer Abstracts of Interest at ESMO 2026
3
FDA Grants Fast Track Designation to Opamtistomig for Advanced Biliary Tract Cancer
4
Dr Hansen on the Integration of CAR T-Cell Therapy Into Earlier Myeloma Treatment Lines
5